Therapeutics
potency also allows for increased profits because of higher yield manufacturing, which makes it advan- tageous from an environmental standpoint as well. Renewed focus has been placed on biologics, biosimilars and biobetters. While biological thera- pies are much more expensive than chemically- derived compounds, they are largely considered by clinicians and payers to be worth their cost, assum- ing that patients can receive them and attain their desired clinical outcome. Many users taking bio- logical therapies have previously failed convention- al therapies and do not have any other therapeutic option. Biological therapies have been established in the European Union (EU) for almost two decades, while in the United States it has taken longer for these therapies to take hold. In fact, only 2% of the US population is using biological thera- pies, even though 40% of prescription drug spend- ing is dedicated to biologicals3. At the same time, profit margins are low and during a five-year peri- od from 2004 to 2009, expenses exceeded sales for biologics. Where once this therapeutic avenue was limited by lack of education, abundant data, robust methods and the issues mentioned above,
regulatory compliance and specific guidance on biologicals is also continuously changing, making the development and manufacturing model more complex. However, due to increased competition and demand for biologics and biosimilars, bio- manufacturing and bioreactor technologies have grown dramatically in current good manufacturing practice (cGMP) manufacturing. Advancements in new processing systems and cellular systems, such as 3D and induced pluripotent stem cell (iPSC) cul- tures and screenings, have allowed researchers to better understand and determine specificity of the biological agents. Now, technologies and mod- elling tools have matured from theory to viable implementation, where industrial production has increased flexibility and reduced costs and is expected to increase by more than 300% in the next five years3.
While the general strategies of success for glob- alising biotherapeutics have left biologicals with a short-term, patented option, pharma is continuing to focus on long-term strategies for sustainable growth and the development of biosimilars and biobetters, complementing existing products and
Join us for the largest drug discovery event in the UK World-class scientific programme
Sponsorship & speaker opportunities - FREE to attend! Registration now open:
www.elrig.org
Drug Discovery World Summer 2017 47
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72